Maryia Zhdanava
9PUBLICATIONS
2CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (9)
Sort by Publication Date:
|Aug 15, 2025
Profiles of Medicaid Beneficiaries with Treatment-Resistant Depression Initiated on Esketamine Nasal Spray.Kristin Clemens, Maryia Zhdanava, Amanda Teeple
|Jan 19, 2025
Mental Health-Related Disability Days and Costs Among Patients with Treatment-Resistant Depression Initiated on Esketamine Nasal Spray and Conventional Therapies in the USA.Manish K Jha, Maryia Zhdanava, Aditi Shah
|Jul 13, 2024
Predictors of High Healthcare Cost Among Patients with Generalized Myasthenia Gravis: A Combined Machine Learning and Regression Approach from a US Payer Perspective.Maryia Zhdanava, Jacqueline Pesa, Porpong Boonmak
|May 10, 2024
Treatment Patterns, Acute Healthcare Resource Use, and Costs of Patients with Treatment-Resistant Depression Completing Induction Phase of Esketamine in the United States.Lisa Harding, Kruti Joshi, Maryia Zhdanava
|Sep 26, 2023
Response to the Letter to the Editor: Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA.Timothy Fitzgerald, Maryia Zhdanava, Dominic Pilon
|Sep 06, 2023
Persistence and Dose Escalation During Maintenance Phase and Use of Nonbiologic Medications Among Patients With Ulcerative Colitis Initiated on Ustekinumab in the United States.Maryia Zhdanava, Ruizhi Zhao, Ameur M Manceur
Pageof 2
